Healthcare -
Medical - Devices - NASDAQ - FR
$ 1.8203
0 %
$ 68.1 M
Market Cap
-2.74
P/E
1. INTRINSIC VALUE
Balance Sheet
EDAP TMS S.A.
| Current Assets | 69.9 M |
| Cash & Short-Term Investments | 29.8 M |
| Receivables | 20.3 M |
| Other Current Assets | 19.8 M |
| Non-Current Assets | 16.2 M |
| Long-Term Investments | 0 |
| PP&E | 10.3 M |
| Other Non-Current Assets | 5.85 M |
| Current Liabilities | 37.8 M |
| Accounts Payable | 12.6 M |
| Short-Term Debt | 9.82 M |
| Other Current Liabilities | 15.4 M |
| Non-Current Liabilities | 7.36 M |
| Long-Term Debt | 4.1 M |
| Other Non-Current Liabilities | 3.26 M |
EFFICIENCY
Earnings Waterfall
EDAP TMS S.A.
| Revenue | 64.1 M |
| Cost Of Revenue | 37.6 M |
| Gross Profit | 26.6 M |
| Operating Expenses | 47.1 M |
| Operating Income | -20.5 M |
| Other Expenses | -1.52 M |
| Net Income | -19 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
EDAP TMS S.A.
| Net Income | -19 M |
| Depreciation & Amortization | 2.56 M |
| Capital Expenditures | -4.1 M |
| Stock-Based Compensation | 3.28 M |
| Change in Working Capital | -1.96 M |
| Others | 3.86 M |
| Free Cash Flow | -17.7 M |
Wall Street Analysts Price Targets
EDAP TMS S.A.
EDAP has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
EDAP does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
EDAP TMS S.A.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
EDAP to Present at the Jefferies Global Healthcare Conference
AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City. Presentation details: Date: Thursday, June 5th Time: 4:20-4:50 PM ET Webcast: https://wsw.com/webcast/jeff319/edap/1824368 The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website here.
globenewswire.com
- 3 weeks ago
EDAP TMS S.A. (EDAP) Q1 2025 Earnings Call Transcript
EDAP TMS S.A. (OTCPK:HAGHY) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants John Fraunces - IR, LifeSci Advisors Ryan Rhodes - CEO Ken Mobeck - CFO Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C.
seekingalpha.com
- 1 month ago
EDAP Reports First Quarter 2025 Financial Results
Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025) Launched the New Focal One i Robotic HIFU System Performed World's First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the first quarter of 2025. “Demand for Focal One remains on a solid growth trajectory, as demonstrated by our strong first quarter system placements.
globenewswire.com
- 1 month ago
EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025
Company to host conference call and webcast on Thursday, May 15 th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer.
globenewswire.com
- 1 month ago
EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting
AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced the positive final results of the Focal Ablation Versus Radical Prostatectomy (FARP) Study, the first randomized controlled trial completed comparing ultrasound energy-based focal ablation versus Robotic Prostatectomy. The study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up.
globenewswire.com
- 1 month ago
EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting
Focal One i expands HIFUsion® patient-specific imaging compatibility to include PSMA PET, ExactVu™ Micro-Ultrasound, along with AI-driven and intelligent algorithms including Unfold AI™ and OnQ™ Prostate Focal One i extends HIFUsion capabilities to integrate Koelis® 3D biopsy maps and DynaCAD Urology datasets Focal One i system will enable future capabilities including treatment streaming and recording, remote collaborative procedures and expanded clinical indications AUSTIN, Texas, April 24, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced the launch of the new Focal One i system at the upcoming 120th American Urological Association (AUA) Annual Meeting being held in Las Vegas, Nevada from April 26-29, 2025. The Focal One i system incorporates important new features and enhanced capabilities including: Expanded HIFUsion compatibility including Prostate-Specific Membrane Antigen (PSMA) PET scans, ExactVu Micro-Ultrasound, Unfold AI® and OnQ Prostate®, as well as extended capabilities for Koelis 3D biopsy maps and DynaCAD Urology datasets Streamlined HIFUsion and treatment workflows with guided, step-by-step procedures designed to improve efficiency Onboard Video Libraries to facilitate sharing standard techniques and clinical best practices Integrated ability to stream and record Focal One i treatments as well as enabling remote proctoring and remote collaborative procedures “The new features and design of the Focal One i system are based directly on the feedback from our customers, as well as anticipating the future needs of surgeons performing focal therapy.
globenewswire.com
- 1 month ago
EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting
Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ablation versus radical prostatectomy as a first-line treatment for prostate cancer Presentation on the first ever remote transatlantic Focal One Robotic HIFU procedure will be given by Ruben Olivares, MD, Urologic Surgeon at the Cleveland Clinic, at the AUA session of the Engineering & Urology Society Notable increase in the number of scientific presentations on focal therapy and ablation in the management of prostate cancer Focal One Robotic HIFU Masterclass will be held at the Keck School of Medicine of the University of Southern California on April 24-25th, prior to AUA Annual Meeting AUSTIN, Texas, April 22, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that Focal One will have its largest presence ever at the upcoming 120th American Urological Association (AUA) Annual Meeting. “This year's AUA meeting promises to be the most significant scientific meeting to date highlighting the growing acceptance and utilization of the Focal One Robotic HIFU platform by the global urology community,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS.
globenewswire.com
- 1 month ago
EDAP TMS S.A. (EDAP) Q4 2024 Earnings Call Transcript
EDAP TMS S.A. (NASDAQ:EDAP ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants John Fraunces - IR, LifeSci Advisors Ryan Rhodes - CEO Ken Mobeck - CFO Conference Call Participants Michael Sarcone - Jefferies Swayampakula Ramakanth - H.C.
seekingalpha.com
- 2 months ago
EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results
Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 U.S. Focal One HIFU procedures grew 51% on a year-over-year basis in 2024 Focal One receives CE Mark for the treatment of deep infiltrating endometriosis Recent landmark HIFI study publication demonstrates positive outcomes with Focal One® Robotic HIFU versus surgery in the management of prostate cancer First patients treated in Phase I/II study evaluating Focal One Robotic HIFU for the treatment of Benign Prostatic Hyperplasia (BPH) Company to host conference call and webcast today, March 27th, at 8:30 a.m. EDT AUSTIN, Texas, March 27, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the fourth quarter and full-year 2024.
globenewswire.com
- 2 months ago
EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
Company to host conference call and webcast on Thursday, March 27 th at 8:30am EDT AUSTIN, Texas, March 6, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on Thursday, March 27th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer.
globenewswire.com
- 3 months ago
EDAP Appoints Glen French to Board of Directors
PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors. “We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS.
globenewswire.com
- 3 months ago
Cortechs.ai and EDAP Announce World's First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center
San Diego, CA and Austin, Texas, February 6, 2025 - Cortechs.ai, an emerging leader in novel imaging solutions for prostate cancer care, and EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced the successful completion of the world's first OnQ Prostate-assisted Focal One® Robotic HIFU procedure at the University of California, San Francisco (UCSF) Prostate Center. This milestone marks the first clinical application of OnQ Prostate's patented RSI technology to guide focal therapy, demonstrating how advanced MR-imaging can improve lesion localization and targeting for urologists performing focal therapy.
globenewswire.com
- 4 months ago
8. Profile
Summary
EDAP TMS S.A. EDAP
COUNTRY
FR
INDUSTRY
Medical - Devices
MARKET CAP
$ 68.1 M
Dividend Yield
0.00%
Description
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
Contact
Parc d’Activites la Poudrette-Lamartine, Vaulx-en-Velin, 69120
https://www.edap-tms.com
IPO
Date
Aug. 1, 1997
Employees
310
Officers
Mr. Francois Dietsch
Chief Accounting Officer
Mr. Ryan Rhodes
Chief Executive Officer & Director
Mr. Jean-Francois Bachelard
President & Chief Executive Officer of Edaptechnomed Co. Ltd.
Mr. Frederic Pech
President of EDAP TMS France
Mr. Carre Emmanuel
Chief Operating Officer
Mr. Ken Mobeck
Chief Financial Officer
Ms. Blandine Confort
Head of Legal Affairs & Investor Relations and Secretary